Presentation to include clinical data from a phase 2 study of Gruticibart (AB023), a factor XI-targeted antibody being developed for the treatment and prevention of thrombosis and inflammation
Read MorePresentation to include clinical data from Aronora's phase 2 study of AB002, a first-in-class protein C activator enzyme that is being developed for the treatment and prevention of thrombotic and inflammatory diseases.
Read MorePresentation to include clinical data from Aronora's phase 2 study of AB023, a factor XI-targeted antibody that is being developed for the treatment and prevention of thrombosis and inflammation.
Read More